XML 15 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2023 $ 6,354 $ 253,056,133 $ (162,231,379) $ 90,831,108 $ 600,380 $ 91,431,488
Balance (in Shares) at Sep. 30, 2023   6,354,371          
Issuance of common stock for services $ 4 76,142 76,146 76,146
Issuance of common stock for services (in Shares)   4,351          
Stock-based compensation expense 3,058,185 3,058,185 3,058,185
Net loss (9,231,185) (9,231,185) 9,231,185
Balance at Dec. 31, 2023 $ 6,358 256,190,460 (171,462,564) 84,734,254 600,380 85,334,634
Balance (in Shares) at Dec. 31, 2023   6,358,722          
Issuance of common stock for services $ 6 98,073 98,079 98,079
Issuance of common stock for services (in Shares)   5,069          
Stock-based compensation expense 3,078,392 3,078,392 3,078,392
Net loss (8,544,154) (8,544,154) (8,544,154)
Balance at Mar. 31, 2024 $ 6,364 259,366,925 (180,006,718) 79,366,571 600,380 79,966,951
Balance (in Shares) at Mar. 31, 2024   6,363,791          
Balance at Sep. 30, 2024 $ 7,247 271,440,421 (201,370,218) 70,077,450 4,024,380 74,101,830
Balance (in Shares) at Sep. 30, 2024   7,247,243          
Issuance of common stock, net of costs $ 480 2,573,571 2,574,051 2,574,051
Issuance of common stock, net of costs (in Shares)   480,000          
Stock-based compensation expense 2,524,824 2,524,824 2,524,824
Net loss (10,281,246) (10,281,246) (10,281,246)
Net loss attributable to non-controlling interest 513,000 513,000 (513,000)
Balance at Dec. 31, 2024 $ 7,727 276,538,816 (211,138,464) 65,408,079 3,511,380 68,919,459
Balance (in Shares) at Dec. 31, 2024   7,727,243          
Issuance of common stock, net of costs $ 1,034 3,464,773 3,465,807 3,465,807
Issuance of common stock, net of costs (in Shares)   1,033,406          
Stock-based compensation expense 2,702,031 2,702,031 2,702,031
Net loss (11,511,505) (11,511,505) (11,511,505)
Net loss attributable to non-controlling interest 595,000 595,000 (595,000)
Balance at Mar. 31, 2025 $ 8,761 $ 282,705,620 $ (222,054,969) $ 60,659,412 $ 2,916,380 $ 63,575,792
Balance (in Shares) at Mar. 31, 2025   8,760,649